How China Is Evolving From Copycat Medicines Into a Producer of Complex Drugs

Johnson & Johnson was impressed enough by Nanjing Legend Biotechnology’s work on an experimental gene therapy that it paid $350 million for the global rights to the cancer treatment.
Source: Wall Street